Sotac Pharmaceuticals Ltd
₹154.05
-5.00%
Delayed · cached 15 min
Fair value analysis
SOTAC
Sotac Pharmaceuticals Ltd
₹90.05
Close used for this calculation
₹170.99Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
57/100
Quality radar
Consensus fair value
₹170.99
Below FV▲ +89.9% against the close used
Model range ₹57.62 – ₹311.66
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹57.62Fair value₹170.99Bull₹311.66
FairClose
52-week traded range
52W low ₹90.0552W high ₹139.65
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
Sotac Pharmaceuticals Ltd closed at ₹90.05, 47.3% below the consensus fair value of ₹170.99 drawn from 9 valuation models.
Financial DNA score 57/100 — Good. P/E of 17.2x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹160.87
+78.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹79.34
-11.9%
√(22.5 × EPS × BVPS)
EPS=5.22, BVPS=53.6 · outside Graham range (P/E 17.2, P/B 1.7) — asset-light, treat as a rough floor
Graham Formula
₹171.10
+90.0%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=13.4%, FD=7%
P/E Fair Value
₹186.35
+106.9%
EPS × 35.7x (sector P/E)
EPS=5.22, Sector P/E=35.7x
Peter Lynch (PEG)
₹69.95
-22.3%
EPS × Growth% (PEG = 1 is fair)
EPS=5.22, g=13.4%
EV/EBITDA
₹311.66
+246.1%
(EBITDA × 16.7x − Net Debt) ÷ Shares
EBITDA=230M
Book Value (P/B)
₹57.62
-36.0%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=53.6, ROE=10.3%, g=6%, r=10%
Reverse DCF
₹90.05
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 5.2% | Historical: 13.4%
Margin of Safety
₹112.06
+24.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=149.42, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.